DelveInsight Business Research, LLP: Neuroendocrine Carcinoma Market Poised for Significant Growth During the Forecast Period (2026-2036) Driven by Rising Incidence and ...

The neuroendocrine carcinoma market is experiencing steady growth driven by rising disease prevalence and improved diagnostic capabilities. Advancements in targeted therapies and immunotherapies ...
Targeted Oncology

Sequencing Therapy for HER2-Positive Metastatic Breast Cancer: Emerging Strategies

PATINA supports adding palbociclib to anti-HER2 plus endocrine therapy in HR+/HER2+ disease, and HER2CLIMB-05 validates tucatinib with HP after THP induction. Sequencing trials must address ADC ...

Study finds no evidence that prostate cancer drugs interact with anticoagulants to increase bleeding, clotting risks

In a study of adults with advanced prostate cancer taking androgen-receptor pathway inhibitors and different types of ...

Neuroendocrine Carcinoma Market Poised for Significant Growth During the Forecast Period (2026-2036) Driven by Rising Incidence and Advancements in Targeted Therapies ...

The neuroendocrine carcinoma market is experiencing steady growth driven by rising disease prevalence and improved diagnostic capabilities. Advancements ...
Renal & Urology News

ASCO GU 2026: Are Combinatorial Therapies the Future Standard of Care in RCC and MIBC?

Investigators are exploring whether combinational therapies can improve survival for patients with renal cell carcinoma or muscle-invasive bladder cancer.

Medicus Pharma Provides Interpretation of Positive Phase 2 SkinJect™ Dataset

The Company Reported 73% Clinical Clearance in the 200-µg cohort at Day 57PHILADELPHIA, March 09, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company"), a ...